Rawle Francis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rawle Francis has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Celia Maria Santi
Department of Obstetrics and Gynecology, Center for Reproductive Health Sciences, Washington University School of Medicine in St. Louis, St. Louis, MO, United States
2 shared publications - Derek J. Hook
Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development College of Pharmacy University of Minnesota 717 Delaware Street, SE Minneapolis MN 55414 USA
2 shared publications - Erick J. Carlson
Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development College of Pharmacy University of Minnesota 717 Delaware Street, SE Minneapolis MN 55414 USA
2 shared publications - Gunda I. Georg
Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States
2 shared publications - Jon E. Hawkinson
Department of Medicinal Chemistry and Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States
2 shared publications - Maximilian D. Lyon
Department of Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, MO 63110, USA
2 shared publications
Latest Publications
- Open Access
- 24 August 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (19) , e202200441
Corrigendum: Discovery and Characterization of Multiple Classes of Human CatSper Blockers
- 24 August 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (19) , e202200441
Open AccessCorrigendum: Discovery and Characterization of Multiple Classes of Human CatSper Blockers
- Open Access
- 14 June 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (15) , e202000499
Discovery and Characterization of Multiple Classes of Human CatSper Blockers
The cation channel of sperm (CatSper) is a validated target for nonhormonal male contraception, but it lacks selective blockers, hindering studies to establish its role in both motility and capacitation. Via an innovative calcium uptake assay utilizing human sperm we discovered novel inhibitors of CatSper function from a high‐throughput screening campaign of 72,000 compounds. Preliminary SAR was established for seven hit series. HTS hits or their more potent analogs blocked potassium‐induced depolarization and noncompetitively inhibited progesterone‐induced CatSper activation. CatSper channel blockade was confirmed by patch clamp electrophysiology and these compounds inhibited progesterone‐ and prostaglandin E1‐induced hyperactivated sperm motility. One of the hit compounds is a potent CatSper inhibitor with high selectivity for CatSper over hCav1.2, hNav1.5, moderate selectivity over hSlo3 and hERG, and low cytotoxicity and is therefore the most promising inhibitor identified in this study. These new CatSper blockers serve as useful starting points for chemical probe development and drug discovery efforts.
- 14 June 2022
- Published by Wiley in ChemMedChem
- Vol. 17 (15) , e202000499
Open AccessDiscovery and Characterization of Multiple Classes of Human CatSper Blockers
The cation channel of sperm (CatSper) is a validated target for nonhormonal male contraception, but it lacks selective blockers, hindering studies to establish its role in both motility and capacitation. Via an innovative calcium uptake assay utilizing human sperm we discovered novel inhibitors of CatSper function from a high‐throughput screening campaign of 72,000 compounds. Preliminary SAR was established for seven hit series. HTS hits or their more potent analogs blocked potassium‐induced depolarization and noncompetitively inhibited progesterone‐induced CatSper activation. CatSper channel blockade was confirmed by patch clamp electrophysiology and these compounds inhibited progesterone‐ and prostaglandin E1‐induced hyperactivated sperm motility. One of the hit compounds is a potent CatSper inhibitor with high selectivity for CatSper over hCav1.2, hNav1.5, moderate selectivity over hSlo3 and hERG, and low cytotoxicity and is therefore the most promising inhibitor identified in this study. These new CatSper blockers serve as useful starting points for chemical probe development and drug discovery efforts.